Trade Report: The Anthera Pharmaceuticals Inc. (ANTH) Raised to Hold at Zacks Investment Research

The Anthera Pharmaceuticals Inc. (ANTH) Raised to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) from a sell rating to a hold rating in a research report released on Tuesday morning.

According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “

Several other equities analysts have also recently issued reports on the stock. Jefferies Group reaffirmed a buy rating on shares of Anthera Pharmaceuticals in a research note on Wednesday, August 10th. HC Wainwright began coverage on shares of Anthera Pharmaceuticals in a research note on Friday, July 8th. They issued a buy rating and a $10.00 price objective on the stock. Finally, FBR & Co reaffirmed a hold rating on shares of Anthera Pharmaceuticals in a research note on Monday, June 20th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $8.70.

Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) opened at 3.01 on Tuesday. The stock has a 50 day moving average of $3.09 and a 200 day moving average of $3.34. The firm’s market cap is $124.70 million. Anthera Pharmaceuticals has a 52-week low of $2.28 and a 52-week high of $7.15.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by $0.04. Anthera Pharmaceuticals had a negative return on equity of 131.24% and a negative net margin of 1,273.45%. Equities analysts predict that Anthera Pharmaceuticals will post ($1.37) EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ProShare Advisors LLC increased its position in Anthera Pharmaceuticals by 3.4% in the second quarter. ProShare Advisors LLC now owns 35,319 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,168 shares during the period. Smith Asset Management Group LP increased its position in Anthera Pharmaceuticals by 69.3% in the second quarter. Smith Asset Management Group LP now owns 49,120 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 20,100 shares during the period. Jefferies Group LLC purchased a new position in Anthera Pharmaceuticals during the second quarter valued at $155,000. HighTower Advisors LLC increased its position in Anthera Pharmaceuticals by 8.0% in the second quarter. HighTower Advisors LLC now owns 50,100 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 3,700 shares during the period. Finally, Rhumbline Advisers increased its position in Anthera Pharmaceuticals by 47.4% in the second quarter. Rhumbline Advisers now owns 56,389 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 18,135 shares during the period. 55.24% of the stock is currently owned by institutional investors and hedge funds.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Related posts

Leave a Comment